Objective:

To evaluate the efficacy of once-daily oral HRS-7535 in reducing hemoglobin A1c levels in patients with type 2 diabetes inadequately controlled with metformin, particularly focusing on the demographic characteristics of the population.

Key Findings:

• HRS-7535 reduced hemoglobin A1c levels significantly compared to placebo, with reductions of 1.19% to 1.82% across different doses (p < 0.05).
• 49% to 63% of patients on HRS-7535 achieved hemoglobin A1c levels below 7.0%, compared to 15% in the placebo group (p < 0.05).
• Rescue antihyperglycemic therapy was required in 3% to 8% of patients receiving HRS-7535, compared to 31% in the placebo group (p < 0.05).
• Gastrointestinal adverse events were common, with nausea occurring in 8% to 34% of patients on HRS-7535.

Interpretation:

The study demonstrated statistically significant reductions in hemoglobin A1c with HRS-7535 in the studied population, suggesting potential benefits for clinical practice, although caution is advised in generalizing results to other populations.

Limitations:

• The trial duration of 16 weeks may not fully capture long-term glycemic responses.
• The study population had a mean body mass index of 26.7, which may not represent higher BMI populations in Western countries, potentially affecting generalizability.
• No formal adjustment for multiplicity was applied, necessitating cautious interpretation of secondary endpoints.

Conclusion:

HRS-7535 shows promise in lowering A1c levels in type 2 diabetes patients, but further studies are needed to confirm efficacy and safety, particularly in diverse populations.